AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Jun 4, 2021
31637_dirs_2021-06-03_8b37e2a8-92bf-4e89-b1c1-a9e745d49bc6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-06-01
Reporting Person: Watts Ryan J. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-01 | Common Stock | S | 13127 | $60.982 | Disposed | 2215948 | Indirect |
| 2021-06-01 | Common Stock | S | 2750 | $62.09 | Disposed | 2213198 | Indirect |
| 2021-06-01 | Common Stock | S | 2102 | $62.755 | Disposed | 2211096 | Indirect |
| 2021-06-01 | Common Stock | S | 354 | $63.50 | Disposed | 2210742 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 156691 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.48 to $61.46 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.50 to $62.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $62.50 to $63.055 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6: Includes 156,691 restricted stock units.